Differential cytokine network profile in polycythemia vera and secondary polycythemia

Muramidase in polycythemia vera.

Immunotherapy and polycythemia vera

Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by abnormal growth of erythroid precursors in the bone marrow. Almost all patients with PV, around 97%, have a mutation in Janus kinase 2 (JAK2). It is through the activation of JAK/Signal Transducers and Activators of Transcription (STAT) protein signaling pathway that the JAK2 mutation is thought to induce cellular ...

Erythropoietic activity in the plasma of patients with polycythemia vera and secondary polycythemia.

\IIRIAM E. SIMPSON P OIAYCYTHI’\IIA VERA is a consditions which is still nsot well unsderst.ood. It has beens shown that. the increase ins the total volunuse of red cells ins this (Ofl(litiOts iS due prinuarily to ais inscreased rat-c of red cell product-ion and not. to an increase ins the life spats of the red cells.m Previously, sic have reported the presenice of ats erythropoietic factor cir...

Treatment of polycythemia vera.

BACKGROUND AND OBJECTIVE Current guidelines for the management of patients with polycythemia vera (PV) derive from a few clinical trials and several uncontrolled clinical studies. The purpose of this paper is to critically review the available evidence in literature for selecting the best treatment in the single patient. METHODS The authors have been working in this field contributing origina...

Pathogenesis of polycythemia vera.

BACKGROUND AND OBJECTIVE Polycythemia vera (PV) is an acquired clonal myeloproliferative disorder characterized by increased production of mature red cells. We still lack a molecular target responsible for this disorder; however, recent investigations have focused on a number of molecules involved in signal transduction pathways mediated by erythropoietin (Epo) and other growth factors. Here we...